Metraipolis › archive › dc_c0abb84bca0b

Heterogeneity in the efficacy of bosentan for hypertensive nephropathy: a study on individualized benefit prediction models based on pathological subtyping… — Europe PMC PMID:41649882

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41649882
DOI
10.1080/07853890.2026.2624240
License (as archived)
solo-consultazione
Archived
2026-11-06T01:43:36.272Z
SHA-256 of the archived text
f6d505388b05b58bfb01d85d0886a5aed6fdb557df55af052db7172ae95bba50
Stable URL of this page
https://metraipolis.com/documento/dc_c0abb84bca0b

How to cite

Heterogeneity in the efficacy of bosentan for hypertensive nephropathy: a study on individualized benefit prediction models based on pathological subtyping… — Europe PMC PMID:41649882 — Europe PMC (en), https://europepmc.org/article/MED/41649882 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_c0abb84bca0b (Metraipolis archive dc_c0abb84bca0b, sha256 f6d505388b05b58bfb01d85d0886a5aed6fdb557df55af052db7172ae95bba50)
BibTeX
@misc{dcc0abb84bca0b,
  title = {Heterogeneity in the efficacy of bosentan for hypertensive nephropathy: a study on individualized benefit prediction models based on pathological subtyping… — Europe PMC PMID:41649882},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41649882},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_c0abb84bca0b; sha256 f6d505388b05b58bfb01d85d0886a5aed6fdb557df55af052db7172ae95bba50},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41649882. Agents can read the archived copy with the MCP tool read_document.